MedPath

Randomized Trial of Transcranial Theta-burst Stimulation and Transcranial Direct Current Stimulation

Not Applicable
Completed
Conditions
Stroke
Registration Number
NCT02031107
Lead Sponsor
Adrian Guggisberg
Brief Summary

Background: Stroke is a leading cause of adult disability. Non-invasive brain stimulation can induce significant and sustained improvements in functional outcome. However the effect is inconsistent and difficult to predict, in particular in the subacute phase after stroke. Although several different stimulation techniques are available, it is unknown which is suitable for which patient.

Objectives: This study has three main objectives:

1. To compare the effects of two techniques of non-invasive brain stimulation (cTBC, continuous theta-burst stimulation; tDCS, direct current transcranial stimulation) on clinical recovery in patients with subacute stroke.

2. To assess the effect of these brain stimulation techniques on brain organization with non-invasive imaging.

3. To find clinical and neural predictors of responsiveness to brain stimulation therapy.

Method: 45 patients with ischemic or hemorrhagic stroke will be randomly assigned to one of 3 groups: cTBS, tDCS, or sham stimulation. Each group will receive the corresponding stimulation therapy 3 times per week for 3 weeks, immediately before intensive physical therapy. Before and after the treatment period, standardized assessments of sensorimotor function areas are obtained together with electroencephalography and functional magnetic resonance recordings. These recordings will be used to analyze and compare the neural effects of each treatment modality.

Clinical Implication: The results of this study might help optimize and individualize stimulation treatment for patients with subacute stroke. It may hence facilitate the transfer of brain stimulation therapy to routine clinical practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • ischemic or hemorrhagic stroke leading to unilateral deficits in motor function with significant impact on independence and daily activities at the beginning of rehabilitation
  • less than 10 weeks after stroke onset.
Exclusion Criteria
  • epileptic seizures
  • metallic objects in the brain
  • presence of implants or neural stimulators
  • pregnancy
  • sleep deprivation
  • recent traumatic brain injury
  • delirium or disturbed vigilance
  • inability to participate in 1h treatment sessions
  • severe language comprehension deficits
  • skull breach
  • new stroke lesions during rehabilitation
  • medical complications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in alpha-band coherence between the affected motor cortex and the rest of the brainWeek 4

Calculated from electroencephalography recordings

Change in compound motor score slope at week 4week 4 after treatment start

The Fugl Meyer motor assessment (FMA), the Nine Hole Peg test (expressed as pegs per minute), and the Jamar dynamometer strength of the affected arm are normalized to the healthy arm and averaged to a compound motor score. This score is obtained twice before treatment (at weeks -1 and 0 relative to treatment start), and twice after treatment (at weeks 4 and 8). Primary outcome measure is the change in slope from week 0 to 4 as compared to the slope between week -1 and 0.

Secondary Outcome Measures
NameTimeMethod
Change in Fugl Meyer Upper Extremity Motor Score at week 8Week 8
Change in activity of daily life scale (motor activity log, MAL)Week 8
Change in Fugl Meyer Upper Extremity Motor Score at week 4Week 4
Number of adverse eventsWeek 8
Change in alpha-band coherence between the unaffected motor cortex and the rest of the brainWeek 4

Trial Locations

Locations (1)

Service de Neurorééducation, Unversity Hospital

🇨🇭

Geneva, Switzerland

Service de Neurorééducation, Unversity Hospital
🇨🇭Geneva, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.